Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615852 | 0.85 | L3MBTL1 (0.64) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL11350777 | 0.82 | L3MBTL1 (0.66) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL4617266 | 0.82 | CYP3A4 (0.64) | L3MBTL1TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6419192 | 0.81 | CYP3A4 (0.62) | L3MBTL1TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL281839 | 0.81 | L3MBTL1 (0.64) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL4846941 | 0.81 | L3MBTL1 (0.69) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL10831761 | 0.81 | L3MBTL1 (0.64) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL18676096 | 0.80 | L3MBTL1 (0.58) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL17293985 | 0.80 | TSHR (0.67) | L3MBTL1KDM4EPKMTSHRMAPK1 | |
| SCHEMBL4616279 | 0.80 | NPC1 (0.61) | L3MBTL1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180854-A1 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | INVION INC (AU) | 2024-06-06 | — | — | US | claimed |
| CN-106390128-B | Use of beta-adrenergic inverse agonists for smoking cessation | 伊沃恩有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-103073522-A | Synthesis method of 2,2' -biazoyl-di (3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt | UNIV JIANGXI NORMAL | 2013-05-01 | — | — | CN | claimed |
| US-7429274-B2 | Agent and method for the oxidative coloring of keratin fibers | WELLA AG (DE) | 2008-09-30 | — | — | US | claimed |
| EP-1601335-B1 | MEANS AND METHOD FOR THE SIMULTANEOUS BLEACHING AND DYEING OF KERATIN FIBRES | WELLA AG (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1699427-B1 | AGENT AND METHOD FOR OXIDATIVELY DYING KERATIN FIBERS | WELLA AG (DE) | 2008-02-27 | — | — | EP | claimed |
| US-7326254-B2 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | WELLA AG (DE) | 2008-02-05 | — | — | US | claimed |
| EP-1599178-B1 | MEANS AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2007-12-19 | — | — | EP | claimed |
| US-7291183-B2 | Agent and method for dyeing keratin fibers | WELLA AG (DE) | 2007-11-06 | — | — | US | claimed |
| US-7244278-B2 | Agent and method for oxidative coloring of keratin fibers | WELLA AG (DE) | 2007-07-17 | — | — | US | claimed |
| US-20070067927-A1 | Agent and method for oxidative coloring of keratin fibers | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2007-03-29 | — | — | US | claimed |
| EP-1599179-B1 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2006-10-11 | — | — | EP | claimed |
| US-20060162096-A1 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2006-07-27 | — | — | US | claimed |
| US-20060010616-A1 | Agent and method for dyeing keratin fibers | Wella GmbH (DE) | 2006-01-19 | — | — | US | claimed |
| WO-1990006372-A1 | SUBSTRATES FOR PEROXIDASE ASSAYING | MICROPROBE CORPORATION (US) | 1990-06-14 | — | — | WO | claimed |
| US-RE32769-E | LEGUMINOUS PLANT GROWTH REGULATORS | MONSANTO COMPANY (US) | 1988-10-18 | — | — | US | claimed |
| CN-222871096-U | Automatic cover rebound structure of medicine dispensing device | 苏州新劢德医疗器械科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119929334-A | Automatic rebound structure of lid and medicine dispensing device | 苏州新劢德医疗器械科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-1990006372-A1 | SUBSTRATES FOR PEROXIDASE ASSAYING | MICROPROBE CORPORATION (US) | 1990-06-14 | — | — | WO | disclosed |
| US-4430420-A | USING AN AMINOSULFONYLHYDRAZONE REDUCING AGENT | EASTMAN KODAK COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060162096-A1 | Means and method for the simultaneous bleaching and dyeing of keratin fibres | KRT18, GPX4, NOX4 | L3MBTL1 4866/4885KDM4E 1120/4885PKM 43/4885 |
| US-20070067927-A1 | Agent and method for oxidative coloring of keratin fibers | KRT18, KIT, AOC1 | L3MBTL1 4883/4885KDM4E 1510/4885PKM 80/4885 |
| US-20240180854-A1 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | ADRB1, ADRB2, ADRB3 | L3MBTL1 3626/4885KDM4E 3528/4885PKM 4176/4885 |
| US-20060010616-A1 | Agent and method for dyeing keratin fibers | KRT18, KIT, MKI67 | L3MBTL1 4881/4885KDM4E 1565/4885PKM 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.